布里瓦-ONE研究:临床实践中布里瓦单一治疗12个月的结果
Vicente Villanueva1, Esther González Villar2, Alejandro Fernandez-Cabrera3
1Hospital Universitario y Politécnic La Fe. Member of ERN EPICARE, Valencia, Spain.
Epilepsia open
|October 29, 2024
概括
布里瓦拉塞坦 (BRV) 单一治疗有效控制了患者的发作,具有高保留率和良好的耐受性. 这种新一代治疗方法对新患者和转换过的患者,包括敏感人群,都有好处.
科学领域:
- 的治疗和管理.
- 对神经系统疾病的药理干预.
- 临床实践中的真实世界的证据.
背景情况:
- 影响全球数以百万计的人,需要有效和耐受良好的治疗方法.
- 布里瓦拉 (BRV) 是一种较新的抗药物,具有独特的作用机制.
- 了解BRV在单一治疗中的实际有效性和耐受性对于临床决策至关重要.
研究的目的:
- 评估布里瓦拉 (BRV) 单疗法在大量多样化的患者队列中的有效性和耐受性.
- 评估BRV作为一线治疗和从其他抗药物转换后的疗效.
- 分析特定患者亚组的结果,包括老年人和患有各种病病因的人.
主要方法:
- 多中心,回顾性,观察性研究,涉及276名西班牙24家医院的成年患者.
- 开始接受BRV单一治疗 (第一线或转换) 的患者被跟踪了12个月.
- 主要终点包括发作自由率和不良事件比例;还进行了保留率和子组分析.
主要成果:
- 观察到高的12个月保留率:整体89.9% (87.5%的第一线,90.4%的转换).
- 77.8%的患者在12个月内实现了无发作 (75%的第一线,78.4%的转化).
- 副作用发生在39.5%的患者中,大多为轻度至中度;最常见的是易怒和头. 在 levetiracetam 切换者,老年患者和具有不同病原因的患者中也观察到类似的结果.
结论:
- 布里瓦拉cetam单疗法在现实环境中显示出显著的有效性和良好的耐受性.
- 对于单一治疗和转换患者从其他抗药物来说,BRV是一种可行的治疗选择.
- 药物的有效性和耐受性扩展到脆弱的患者群体,支持其广泛的临床实用性.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
258
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
258
01:20Antiepileptic Drugs: Potassium Channel Activators
147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
147
01:30Electroconvulsive Therapy
25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25
01:14Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
01:11Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K